Notizie AIOM – anno XV
FDA Grants Full Approval to Frontline Palbociclib in Breast Cancer
March 31, 2017 - The FDA has granted a full approval to palbociclib for use in combination with letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer. The full approval of the CDK 4/6 inhibitor is based on the ...Leggi tutto
FDA Submission Completed for Axicabtagene Ciloleucel in NHL
April 1, 2017 - A biologics license application (BLA) has been submitted for axicabtagene ciloleucel (KTE-C19) as a potential treatment for transplant ineligible patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL), according to Kite Pharma, the developer ...Leggi tutto
FDA Accepts Ibrutinib Application for GVHD
April 4, 2017 - The FDA has accepted a supplemental new drug application (sNDA) for ibrutinib as a treatment for patients with chronic graft-versus-host-disease (cGVHD) after failure of 1 or more lines of systemic therapy, according to Janssen and AbbVie, the codevelopers ...Leggi tutto
FDA Grants Priority Review to CTL019 for ALL
March 29, 2017 - The FDA has granted a priority review designation to tisagenlecleucel-T (CTL019) as a treatment for pediatric and young adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia (ALL), making it the first CAR T-cell therapy to enter ...Leggi tutto
Dabrafenib/Trametinib Combo Wins EU Approval for BRAF+ NSCLC
April 3, 2017 - The European Union (EU) approved the combination of dabrafenib and trametinib for patients with BRAF V600-positive advanced or metastatic non–small cell lung cancer (NSCLC). Novartis, maker of both drugs, reported in a statement that this is the first ...Leggi tutto
Long and Winding Road of Cancer and Pregnancy: A Need for Action
Cancer treatment in a pregnant woman is still a matter of debate, because life-saving therapies for the mother raise concerns about potential detrimental effects for the developing fetus. Recent data support the administration of chemotherapy from 14 weeks gestational age ...Leggi tutto
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
In addition to prospective trials for non–small-cell lung cancers (NSCLCs) that are driven by less common genomic alterations, registries provide complementary information on patient response to targeted therapies. Here, we present the results of an international registry ...Leggi tutto
ASCO and Cancer Care Ontario Update Guideline on Radiation Therapy for Prostate Cancer
March 28, 2017 - The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy for patients with prostate cancer. The update provides evidence-based recommendations for different patient ...Leggi tutto
ASCO Fights Perception That Independents Get Short Shrift
March 30, 2017 - ASCO is working hard to overcome a perception that it has not been truly representative of smaller, independent oncology practices throughout the United States, said Daniel F. Hayes, MD, president of the ASCO, which is the largest association of working ...Leggi tutto